Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Tokyo, December 15, 2023

FOR IMMEDIATE RELEASE

Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan

Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announces the top-line results of Phase 3 comparative study for TO-208, conducted in Japan, for the treatment of molluscum contagiosum.

Torii signed an exclusive license agreement with Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq:VRCA) for the development and commercialization of Verrica's skin disease treatment drug VP-102(TO-208) in Japan on March 17, 2021.

This study is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 Days for up to 4 applications in patients with molluscum contagiosum. The top-line

results show that the proportion of subjects achieving complete clearance of all treatable

molluscum lesions at the completion of the confirmatory study, the primary endpoint of efficacy, has met statistical superiority to placebo. The safety of TO-208was confirmed and there were no observed issues of tolerability for the application.

Torii will aim to submit a manufacturing and marketing application for TO-208 in Japan, based on the results of the study and other studies currently being conducted.

ABOUT VP-102

VP-102 is a topical treatment for molluscum contagiosum containing cantharidin as an active ingredient. Verrica distributes VP-102 under the brand name YCANTHTM in the U.S. and has completed a Phase 2 clinical study of VP-102 for the treatment of common warts in the U.S..

Contact for Torii Pharmaceutical Co., Ltd.: Corporate Planning Department (Public Relations)

Torii Pharmaceutical Co., Ltd. Tokyo: [phone]

E-mail:[e-mail]